Compare CETY & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | CTXR |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 13.4M |
| IPO Year | 2020 | 2010 |
| Metric | CETY | CTXR |
|---|---|---|
| Price | $0.91 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.0K | ★ 258.4K |
| Earning Date | 11-18-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $957,633.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.37 |
| 52 Week High | $2.98 | $1.60 |
| Indicator | CETY | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 53.77 |
| Support Level | $0.88 | $0.48 |
| Resistance Level | $1.02 | $0.61 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 54.17 | 62.85 |
Clean Energy Technologies Inc develop renewable energy products and solutions and establish partnerships in renewable energy that make environmental and economic sense. Its segments are Waste Heat Recovery Solutions - It recycle wasted heat produced in manufacturing, waste to energy and power generation. Waste to Energy Solutions - It convert waste products created in manufacturing, agriculture, wastewater treatment plants and other industries to electricity, renewable natural gas hydrogen and bio char. Engineering, Consulting and Project Management Solutions - It provide power generation, waste to energy, and heat recovery, Procurement and Construction (EPC) services to municipal and industrial customers. It generates majority of revenue from United States followed by International.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.